Search results
5 paź 2022 · Intravenous immune globulin (IVIG) for the treatment of dermatomyositis has not been extensively evaluated. We conducted a randomized, placebo-controlled trial involving patients with active...
18 cze 2019 · Systemic corticosteroid is the first-line treatment for DM; however, other agents such as anti-malaria, IVIG, and immunosuppressive therapies have been used successfully. Keywords: dermatomyositis, autoimmune disease, rare skin condition, calcinosis, polymyositis
This report focused on the efficacy of IVIg for treatment of muscle weakness, with cutaneous disease activity assessed as a secondary endpoint using the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI).
17 sty 2024 · Results from this study demonstrate that IVIg has a favourable safety profile for treatment of adult dermatomyositis patients and provides evidence that will help to inform treatment choice for these patients.
19 lut 2020 · This article argues why the IVIg therapy still retains its value as an unreplaceable treatment option in certain specific subtypes of idiopathic immune myositis patients as well as in certain specific clinical idiopathic immune myositis scenarios.
Intravenous immunoglobulin, a well-established treatment in dermatomyositis, has regained prominence and a large randomized clinical trial has reaffirmed its efficacy, confirming it as an effective therapeutic option in this group of patients.
17 sie 2021 · On July 15, the U.S. Food & Drug Administration (FDA) approved a 10% solution of a human intravenous immunoglobulin (IVIG), Octagam 10%, to treat adults with dermatomyositis, a rare chronic systemic autoimmune disease with a characteristic skin rash and progressive proximal muscle weakness. 1,2 This treatment was previously FDA approved to ...
